We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





Oversensitive COVID-19 Tests Detecting Dead Coronavirus Cells, Driving False Positives and Reinfections

By LabMedica International staff writers
Posted on 07 Sep 2020
Print article
Illustration
Illustration
A study by the Oxford University’s Centre for Evidence-Based Medicine (Oxford, England) suggests that the current COVID-19 diagnostic tests could be too sensitive and may be detecting dead coronavirus cells, leading to overestimated infections.

According to the researchers, the tests used to diagnose COVID-19 are so sensitive that they may be indicating people are infected with SARS-CoV-2 even when they had the virus 70 days ago. Prof Carl Heneghan, director of the Centre for Evidence-Based Medicine, believes that eight days after contracting COVID-19, the chances of an infected person passing on the virus to others become zero if there are no symptoms. However, fragments of the coronavirus can still remain in the body for several weeks afterwards.

Polymerase chain reaction (PCR) tests currently used to detect SARS-CoV-2 have technical limitations as they cannot distinguish whether the virus in the patient is alive or dead. The researchers analyzed 25 studies on PCR tests and found that such tests can suggest people are infected even after their bodies’ immune system has already fought off the coronavirus because these tests only provide a ‘yes’ or ‘no’ as to whether the virus material is in the body. This means such people would test positive even though the coronavirus in their bodies may be harmless and non-infectious.

"After about day eight, you can still find the RNA fragments," Prof Heneghan told BBC Radio 4's Today program. "Some studies have reported up to 70 days that you intermittently shed. You can understand the importance of this, because what you want to do is find those with active infection and not those with the RNA fragments."

“Evidence is mounting that a good proportion of ‘new’ mild cases and people re-testing positive after quarantine or discharge from hospital are not infectious, but are simply clearing harmless virus particles which their immune system has efficiently dealt with,” added Prof Heneghan.

Earlier, a team of South Korean researchers had revealed that reports of recovered coronavirus patients testing positive for SARS-CoV-2 infection a second time round were most likely due to dead-virus fragments. They found that 260 people who had recovered and were declared virus-free tested positive again in South Korea but had little or no contagiousness at all. This meant that they were incapable of transmitting the virus to others, based on virus culture cells that all failed to find live viruses in the recovered patients.

“PCR testing that amplifies genetics of the virus is used in Korea to test COVID-19, and relapse cases are due to technical limits of the PCR testing. The respiratory epithelial cell has a half-life of up to three months, and RNA virus in the cell can be detected with PCR testing one to two months after the elimination of the cell,” said Oh Myoung-don, who spearheads the central clinical committee for emerging disease control in South Korea.

Related Links:
Oxford University’s Centre for Evidence-Based Medicine

Gold Member
COVID-19 TEST READER
COVID-19-CHECK-1 EASY READER+
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
New
Creatine Kinase-MB Assay
CK-MB Test

Print article

Channels

Clinical Chemistry

view channel
Image: Professor Nicole Strittmatter (left) and first author Wei Chen stand in front of the mass spectrometer with a tissue sample (Photo courtesy of Robert Reich/TUM)

Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication

Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more

Molecular Diagnostics

view channel
Image: Health Canada has approved SPINEstat, a first-in-class diagnostic blood test for axSpA, as a Class II medical device (Photo courtesy of Augurex)

First-in-Class Diagnostic Blood Test Detects Axial Spondyloarthritis

Axial spondyloarthritis (axSpA) is a chronic inflammatory autoimmune condition that typically affects individuals during their most productive years, with symptoms often emerging before the age of 45.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.